ライフサイエンスコーパス: pancreatic fistula

1 dpoint was clinically relevant postoperative pancreatic fistula.

2 ine secretions and may prevent postoperative pancreatic fistula.

3 reases the occurrence of clinically relevant pancreatic fistula.

4 ding to the International Study Group on the Pancreatic Fistula.

5 pancreas is a risk factor for postoperative pancreatic fistula.

6 validate the ISGPF classification scheme for pancreatic fistula.

7 g factor in the development of postoperative pancreatic fistula.

8 ained group, 11 patients (12.5%) developed a pancreatic fistula.

9 of complications or a decreased incidence of pancreatic fistula.

10 morbidity (36% vs 63%) and no postoperative pancreatic fistulas.

11 .12-0.76; P = .03) and reduced the number of pancreatic fistulas (10% vs 70%; RD, 0.60; 95% CI, 0.17-

12 being early delayed gastric emptying (19%), pancreatic fistula (14%), and wound infection (10%).

13 7%; P = 0.01), and lower rates of grade >/=3 pancreatic fistula (16% vs 20%; P = 0.05).

14 ference in clinically relevant postoperative pancreatic fistula (18% vs 12%, P = 0.11) or mortality (

15 in part to a significantly increased rate of pancreatic fistulas (18.4% PI versus 8.5% NI, P < 0.001)

16 cations (15 [21%] vs 19 [15%], P = 0.24) and pancreatic fistulas (20 [28%] vs 41 [32%], P = 0.62) wer

17 .01), but worse surgical results with higher pancreatic fistula (21.1% vs 14.6%; P < 0.01) and mortal

18 e new-onset insulin-dependent diabetes (8%), pancreatic fistula (5%), intraabdominal abscess (4%), sm

19 3.3% [P < .001], respectively), incidence of pancreatic fistula after 40 cases (27.5% vs 14.4%; P = .

20 er drainage as first intervention for severe pancreatic fistula after pancreatoduodenectomy was assoc

21 d with relaparotomy as primary treatment for pancreatic fistula after pancreatoduodenectomy.

22 egarding the relative risks of mortality and pancreatic fistula after these procedures.

23 ations including intra-abdominal abscess and pancreatic fistula (all P < 0.02).

24 Biochemical evidence of pancreatic fistula alone has no clinical consequence and

25 rates of early delayed gastric emptying and pancreatic fistula and a significantly longer mean posto

26 mortality, clinically relevant postoperative pancreatic fistula and wound infection, length of stay,

27 s still occur (eg, delayed gastric emptying, pancreatic fistula, and biliary strictures).

28 argin positivity, incidence of postoperative pancreatic fistula, and mortality.

29 Pancreatic fistulas are the most common source of periop

30 GPF has proposed a classification scheme for pancreatic fistula based on clinical parameters; yet it

31 erative length of hospital stay and rates of pancreatic fistula, blood transfusion, and readmission w

32 PPFCs associated with pancreatic fistula carry a greater risk for pancreas gra

33 First intervention for pancreatic fistula: catheter drainage or relaparotomy.

34 PF (ISGPF [The International Study Group on Pancreatic Fistula] classification Grade B or C) occurre

35 Pancreatic fistula continues to be a major cause of post

36 ncrease the incidence of clinically relevant pancreatic fistula (CR-POPF) compared with OPD.

37 ed with reduced rates of clinically relevant pancreatic fistula (CR-POPF)-the most common and morbid

38 complication after PD - clinically relevant pancreatic fistula (CR-POPF).

39 n expected when International Study Group on Pancreatic Fistula criteria were strictly applied, altho

40 PF according to International Study Group on Pancreatic Fistula criteria.

41 s that RPD is noninferior to OPD in terms of pancreatic fistula development and other major postopera

42 This analysis of pancreatic fistulas following pancreatoduodenectomy demo

43 l injury and increased risk of postoperative pancreatic fistula formation.

44 significant PF (International Study Group on Pancreatic Fistula Grade B or C) and hospital-related in

45 e mortality and International Study Group on Pancreatic Fistula grade B/C postoperative pancreatic fi

46 The International Study Group on Pancreatic Fistula grade C fistula rate was 4%.

47 Secondary endpoints were clinically relevant pancreatic fistula (grade B/C), mortality, morbidity, an

48 Clinically relevant pancreatic fistula (grade B/C: drain 11.9%, no-drain 5.7

49 ver, its impact on major outcomes, including pancreatic fistula, has yet to be adequately compared wi

50 ata suggest that patients with postoperative pancreatic fistula have (1) increased pancreatic fat and

51 embolisms in 2 patients and hemorrhage after pancreatic fistula in 1 patient).

52 d with early graft pancreatitis in 18 (50%), pancreatic fistula in 20 (56%, 9 with obvious duodenal s

53 four reported significantly lowered rates of pancreatic fistula in patients receiving prophylactic oc

54 icantly reduces the incidence of significant pancreatic fistula in patients undergoing left pancreate

55 Factors associated with postoperative pancreatic fistula include a soft pancreas, a small panc

56 Postoperative pancreatic fistula is a major contributor to complicatio

57 Postoperative pancreatic fistula is a potentially life-threatening com

58 n system of the International Study Group of Pancreatic Fistula (ISGPF) lacks prognostic capacity reg

59 The primary end point was the development of pancreatic fistula, leak, or abscess of grade 3 or highe

60 The rate of grade 3 or higher postoperative pancreatic fistula, leak, or abscess was significantly l

61 rate of clinically significant postoperative pancreatic fistula, leak, or abscess.

62 my (16%) were the most common procedures and pancreatic fistula occurred in 18% of patients.

63 A persistent pancreatic fistula occurred in 66 of the 79 patients (84

64 Pancreatic fistulas occurred more frequently after enucl

65 tive complications (ODP, 50%; MIDP, 39%) and pancreatic fistula (ODP, 29%; MIDP, 21%).

66 octreotide does not reduce the incidence of pancreatic fistula or total complications after pancreat

67 ominal bleeding, enterocutaneous fistula, or pancreatic fistula) or death.

68 d by the ISGPF (International Study Group on Pancreatic Fistula) pancreatic leak grading system.

69 This was associated with a 56% reduction in pancreatic fistula/pancreatic leak/abscess (PF/PL/A) (21

70 The pancreatic fistula patients were less likely (P < 0.05)

71 ministration of pasireotide for reduction of pancreatic fistula (PF).

72 iated with higher frequency of postoperative pancreatic fistula (POPF) (48.1% vs 27.7%, P = 0.012) an

73 osts of clinically significant postoperative pancreatic fistula (POPF) and to evaluate the cost-effec

74 Postoperative pancreatic fistula (POPF) represents the most significan

75 n Pancreatic Fistula grade B/C postoperative pancreatic fistula (POPF).

76 , 276 patients (14%) developed postoperative pancreatic fistula (POPF).

77 Postoperative pancreatic fistulas (POPFs), postpancreatectomy hemorrha

78 Postoperative complications including pancreatic fistula predicted higher rates of readmission

79 yze the impact of teres ligament covering on pancreatic fistula rate after distal pancreatectomy (DP)

80 and superior in terms of clinically relevant pancreatic fistula rate and fistula-associated complicat

81 f 3.3%, a clinically significant (grade B/C) pancreatic fistula rate of 6.9%, and a median length of

82 The pancreatic fistula rate was significantly lower in the P

83 duodenal resections, and all trials had high pancreatic fistula rates (>19%) in the placebo group.

84 Pancreatic fistula rates are similar for OLP and LLP.

85 The pancreatic fistula rates were 9% in the control group an

86 red in 15%of patients and were due mainly to pancreatic fistula, requiring 10 radiologic drainage pro

87 een markedly reduced, whereas others such as pancreatic fistula still remain a problem.

88 The primary postoperative endpoints were pancreatic fistula, total complications, death, and leng

89 ncreatitis, indications for IAT were grade C pancreatic fistula (treated with completion or left panc

90 Definitions of postoperative pancreatic fistula vary widely, precluding accurate comp

91 Pancreatic fistula was defined by ISGPF criteria.

92 urviving grafts showed that the incidence of pancreatic fistula was greater in the former (90% pancre

93 Forty patients with and without a pancreatic fistula were identified from an Indiana Unive

94 creatoduodenectomy, 309 patients with severe pancreatic fistula were included.

95 previously validated Fistula Risk Score, and pancreatic fistulas were stratified by International Stu

96 s a result of the late diagnosis of a native pancreatic fistula with cholestatic damage to the reduce

97 imilar rates of other complications, such as pancreatic fistula, wound infection, intraabdominal absc